Skip to content

Investors Overview

Esperion Therapeutics is passionately committed to developing and commercializing complementary, oral therapies for patients and physicians globally that could potentially significantly reduce elevated levels of low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia inadequately treated with current lipid-modifying therapies. Bempedoic acid, Esperion-discovered and developed, brings a targeted mechanism of action to the space that could potentially address unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly".

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on May 22, 2017
Last Price 33.76 Change +0.45(+1.351%) open 33.80 Day High 34.47 52-Week High 48.21
Volume 720,852 Previous Close 33.31 Day Low 32.19 52-Week Low 9.40

Press Releases

Load More